Inotiv, Inc. (NOTV)
Largest Insider Buys in Sector
NOTV Stock Price History Chart
NOTV Stock Performance
About Inotiv, Inc.
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method …
Insider Activity of Inotiv, Inc.
Over the last 12 months, insiders at Inotiv, Inc. have bought $728,270 and sold $0 worth of Inotiv, Inc. stock.
On average, over the past 5 years, insiders at Inotiv, Inc. have bought $315,641 and sold $95,143 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Landman David (director) — $513,998. Beattie John Gregory (Chief Operating Officer) — $142,500. Harrington Michael J (director) — $119,466.
The last purchase of 23,529 shares for transaction amount of $99,998 was made by Landman David (director) on 2024‑12‑19.
List of Insider Buy and Sell Transactions, Inotiv, Inc.
| 2024-12-19 | director | 23,529 0.1017% | $4.25 | $99,998 | -1.72% | |||
| 2024-12-10 | Chief Operating Officer | 30,000 0.1149% | $4.75 | $142,500 | +3.10% | |||
| 2024-12-10 | director | 7,500 0.0258% | $4.26 | $31,950 | +3.10% | |||
| 2024-12-06 | director | 100,000 0.4232% | $4.14 | $414,000 | +27.37% | |||
| 2024-12-06 | director | 10,000 0.0407% | $3.98 | $39,822 | +27.37% | |||
| 2023-12-14 | Chief Operating Officer | 47,966 0.1875% | $3.12 | $149,836 | +9.07% | |||
| 2023-12-14 | Chief Commercial Officer | 5,000 0.0177% | $2.83 | $14,145 | +9.07% | |||
| 2023-03-14 | Chief Strategy Officer | 5,100 0.0207% | $4.91 | $25,041 | -12.26% | |||
| 2023-02-22 | Chief Operating Officer | 5,000 0.0188% | $6.99 | $34,950 | -42.90% | |||
| 2022-12-09 | Sale | Chief Human Resources Officer | 2,123 0.0085% | $5.82 | $12,366 | -13.38% | ||
| 2022-12-01 | Sale | director | 1,000 0.0042% | $6.12 | $6,120 | -13.42% | ||
| 2022-11-01 | Sale | director | 1,000 0.004% | $21.12 | $21,123 | -74.83% | ||
| 2022-10-17 | Sale | director | 1,000 0.0038% | $19.10 | $19,100 | -72.52% | ||
| 2022-03-15 | Chief Operating Officer, RMS | 4,049 0.0148% | $18.84 | $76,283 | -22.37% | |||
| 2021-12-22 | Sale | Sr. VP, Preclinical Srvcs. | 3,057 0.0141% | $43.04 | $131,577 | -56.03% | ||
| 2021-02-24 | President and CEO | 5,000 0.0442% | $14.42 | $72,100 | +96.38% | |||
| 2021-02-23 | Chief Operating Officer | 8,288 0.0719% | $14.00 | $116,032 | +98.69% | |||
| 2020-08-19 | Chief Strategy Officer | 3,733 0.0349% | $4.75 | $17,732 | +229.17% | |||
| 2020-08-19 | director | 5,000 0.0468% | $4.75 | $23,750 | +229.17% | |||
| 2020-06-15 | President and CEO | 2,884 0.0258% | $5.20 | $14,997 | +36.21% |
Insider Historical Profitability
| Landman David | director | 176851 0.5524% | $4.53 | 2 | 0 | |
| Beattie John Gregory | Chief Operating Officer | 161761 0.5053% | $4.53 | 4 | 0 | +27.9% |
| Brown Nigel | director | 65537 0.2047% | $4.53 | 1 | 0 | |
| Harrington Michael J | director | 37500 0.1171% | $4.53 | 1 | 0 | |
| Sagartz John E | Chief Strategy Officer | 692047 2.1616% | $4.53 | 3 | 0 | +99.88% |
Institutional Investor Ownership
| The Vanguard Group | $11.42M | 4.02 | 1.04M | +0.98% | +$110,997.25 | <0.0001 | |
| Millennium Management LLC | $5.29M | 1.86 | 483,796 | +91.3% | +$2.53M | <0.01 | |
| Ameriprise Financial | $4.91M | 1.73 | 449,159 | +301.54% | +$3.69M | <0.01 | |
| Goldman Sachs | $2.45M | 0.86 | 223,730 | +546.86% | +$2.07M | <0.0001 | |
| Geode Capital Management | $2.39M | 0.84 | 218,230 | +13.49% | +$283,774.73 | <0.0001 |